Infectious keratitis treated with corneal crosslinking

Cornea

Volumn 29, Issue 12, 2010, Pages 1353-1358

  Makdoumi, Karim ^a   Mortensen, Jes ^a   Crafoord, Sven ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

corneal melting; crosslinking; CXL; keratitis; riboflavin; ultraviolet A; UV A

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; COLLAGEN; DEXAMETHASONE; GENTAMICIN; LEVOFLOXACIN; PREDNISOLONE; RIBOFLAVIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTACT LENS; CORNEA EDEMA; CORNEA ULCER; CORNEAL COLLAGEN CROSSLINKING; CROSS LINKING; DISEASE SEVERITY; DRUG MEGADOSE; EPITHELIZATION; EYE CARE; FOLLOW UP; HUMAN; HYPOPYON; KERATITIS; PRIORITY JOURNAL; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; COLLAGEN; CORNEAL STROMA; CORNEAL ULCER; CROSS-LINKING REAGENTS; EYE INFECTIONS, BACTERIAL; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MIDDLE AGED; MORAXELLA; MORAXELLACEAE INFECTIONS; PHOTOSENSITIZING AGENTS; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 78650427403     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181d2de91     Document Type: Article

References (36)

1. Wollensak G. Crosslinking treatment of progressive keratoconus: New hope. Curr Opin Ophthalmol. 2006;17:356-360.
2. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003; 135:620-627.
3. Kanellopoulos AJ, Binder PS. Collagen cross-linking (CCL) with sequential topography-guided PRK: A temporizing alternative for keratoconus to penetrating keratoplasty. Cornea. 2007;26:891-895.
4. Hafezi F, Kanellopoulos J,Wiltfang R, et al. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. J Cataract Refract Surg. 2007;33:2035-2040.
5. Caporossi A, Baiocchi S, Mazzotta C, et al. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: Preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006;32:837-845.
6. Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta. 1965;103:360-363.
7. Corbin F III. Pathogen inactivation of blood components: Current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol. 2002;76(Suppl 2):253-257.
8. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877-885.
9. Cardo LJ, Rentas FJ, Ketchum L, et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang. 2006;90:85-91.
10. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000;78(Suppl 2):211-215.
11. Cardo LJ, Salata J, Mendez J, et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci. 2007;37:131-137.
12. Goodrich RP, Edrich RA, Li J, et al. The Mirasol PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci. 2006;35:5-17.
13. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15-21.
14. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45:1335-1341.
15. Picker SM, Steisel A, Gathof BS. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion. 2008;48:1685-1692.
16. Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008;22:133-153.
17. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogenreduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45:911-919.
18. Spoerl E, Wollensak G, Seiler T. Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res. 2004;29:35-40.
19. Schilde T, Kohlhaas M, Spoerl E, et al. Enzymatic evidence of the depth dependence of stiffening on riboflavin/UVA treated corneas [in German]. Ophthalmologe. 2008;105:165-169.
20. Schnitzler E, Spörl E, Seiler T. Bestrahlung der Hornhaut mit UV-Licht und Riboflavingabe als neuer Behandlungsversuch bei einschmelzenden Hornhautprozessen, erste Ergebnisse bei vier Patienten. Klin Monatsbl Augenheilkd. 2000;217:190-193.
21. Martins SA, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: A potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49:3402-3408.
22. Iseli HP, Thiel MA, Hafezi F, et al. Ultraviolet A/riboflavin corneal crosslinking for infectious keratitis associated with corneal melts. Cornea. 2008;27:590-594.
23. Moshirfar M, Meyer JJ, Espandar L. Fourth-generation fluoroquinoloneresistant mycobacterial keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2007;33:1978-1981. (Pubitemid 47615385)
24. Mamalis N. The increasing problem of antibiotic resistance. J Cataract Refract Surg. 2007;33:1831-1832.
25. de la Cruz J, Behlau I, Pineda R. Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy. J Cataract Refract Surg. 2007;33:1318-1321.
26. Höfling-Lima AL, de Freitas D, Sampaio JL, et al. In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil. Cornea. 2005;24:730-734.
27. Moshirfar M, Mirzaian G, Feiz V, et al. Fourth-generation fluoroquinolone- resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg. 2006;32:515-518.
28. Jhanji V, Sharma N, Satpathy G, et al. Fourth-generation fluoroquinoloneresistant bacterial keratitis. J Cataract Refract Surg. 2007;33:1488-1489.
29. McGhee CN, Niederer R. Resisting susceptibility: Bacterial keratitis and generations of antibiotics. Clin Experiment Ophthalmol. 2006;34:3-5. No abstract available.
30. Green M, Apel A, Stapleton F. A longitudinal study of trends in keratitis in Australia. Cornea. 2008;27:33-39.
31. Wollensak G, Iomdina E, Dittert DD, et al. Wound healing in the rabbit cornea after corneal collagen cross-linking with riboflavin and UVA. Cornea. 2007;26:600-605.
32. Wollensak G, Spoerl E,Wilsch M, et al. Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment. Cornea. 2004;23: 43-49.
33. Wang F. UVA/Riboflavin-induced apoptosis in mouse cornea. Ophthalmologica. 2008;222:369-372.
34. Bertollo CM, Oliveira AC, Rocha LT, et al. Characterization of the antinociceptive and anti-inflammatory activities of riboflavin in different experimental models. Eur J Pharmacol. 2006;547:184-191.
35. Takami Y, Gong H, Amemiya T. Riboflavin deficiency induces ocular surface damage. Ophthalmic Res. 2004;36:156-165.
36. Erratum in: Ophthalmic Res. 2004;36:299-302.